Claims for Patent: 9,540,410
✉ Email this page to a colleague
Summary for Patent: 9,540,410
Title: | Gemcitabine prodrugs and uses thereof |
Abstract: | The present invention provides compounds according to formula I: ##STR00001## and pharmaceutically acceptable salts thereof. For compounds of formula I, R.sup.1 and R.sup.2 are independently selected from the group consisting of H, --C(.dbd.O)--(CH.sub.2).sub.2-aryl, and --C(.dbd.O)--(CH.sub.2).sub.n--C(.dbd.O)--NH-aryl. The subscript n is from 2 to 6. R.sup.3 is selected from the group consisting of H and --C(.dbd.O)--O--R.sup.4; and R.sup.4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl and substituted heteroalkyl. Compounds are provided wherein at least one of R.sup.1 and R.sup.2 is other than H. Pharmaceutical compositions, methods for inhibiting the growth of cancer cells, and methods for the treatment of cancer are also provided. |
Inventor(s): | Wu; Laurence I. (Taipei, TW) |
Assignee: | BOYEN THERAPEUTICS, INC. (Taipei, TW) |
Application Number: | 14/599,166 |
Patent Claims: | 1. A method for treating cancer selected from the group consisting of pancreatic cancer, non-small cell lung cancer, breast cancer, ovarian cancer, bladder cancer, and
colorectal cancer in a subject in need thereof by inhibiting the growth of cancer cells, the method comprising administering to the subject an effective amount of a pharmaceutical composition comprising a compound according to formula I: ##STR00113## or
a pharmaceutically acceptable salt thereof; wherein R.sup.1 and R.sup.2 are independently selected from the group consisting of H, --C(.dbd.O)--(CH.sub.2).sub.2--Ar and --C(.dbd.O)--(CH.sub.2).sub.n--C(.dbd.O)--NH--Ar, and at least one of R.sup.1 and
R.sup.2 is other than H, and Ar is aryl or heteroaryl; R.sup.3 is selected from the group consisting of H and --C(.dbd.O)--O--R.sup.4; R.sup.4 is selected from the group consisting of alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl,
substituted alkynyl, arylalkyl, substituted arylalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, heteroalkyl and substituted heteroalkyl; and the subscript n is an integer of from 2 to 6.
2. A method according to claim 1, wherein R.sup.1 and R.sup.2 are independently selected from the group consisting of H, --C(.dbd.O)--(CH.sub.2).sub.2--Ar and --C(.dbd.O)--(CH.sub.2).sub.n--C(.dbd.O)--NH-phenyl, and at least one of R.sup.1 and R.sup.2 is other than H, and Ar is phenyl or 3-pyridyl; and the subscript n is 2, 4 or 6. 3. A method according to claim 1, wherein R.sup.2 and R.sup.3 are H. 4. A method according to claim 2, wherein R.sup.2 is H and R.sup.1 and R.sup.3 are other than H. 5. A method according to claim 2, wherein R.sup.1 is H and R.sup.2 and R.sup.3 are other than H. 6. A method according to claim 4, wherein R.sup.4 is selected from the group consisting of alkyl and substituted alkyl. 7. A method according to claim 5, wherein R.sup.4 is selected from the group consisting of alkyl and substituted alkyl. 8. A method according to claim 6, wherein R.sup.4 is C.sub.1-C.sub.8 alkyl. 9. A method according to claim 7, wherein R.sup.4 is C.sub.1-C.sub.8 alkyl. 10. A method according to claim 4, wherein R.sup.4 is C.sub.3-C.sub.8 heteroalkyl. 11. A method according to claim 5, wherein R.sup.4 is C.sub.3-C.sub.8 heteroalkyl. 12. A method according to claim 1, further comprising administering to the subject an anti-cancer agent. 13. A method according to claim 12, wherein the anti-cancer agent is selected from the group consisting of a conventional chemotherapeutic agent, a targeted therapeutic agent, a radiotherapeutic agent and a mixture thereof. 14. A method according to claim 12, wherein the anti-cancer agent is selected from the group consisting of cisplatin, oxaliplatin, carboplatin, erlotinib, gefitinib, lapatinib, cetuximab, zalutumumab, minotuzumab, and matuzumab. 15. A method according to claim 1, wherein administering the composition is conducted orally. 16. A method according to claim 1, wherein administering the composition is conducted parenterally. 17. A method according to claim 1, wherein the compound has the formula: ##STR00114## or a pharmaceutically acceptable salt thereof. 18. A method according to claim 1, wherein the compound has the formula: ##STR00115## or a pharmaceutically acceptable salt thereof. 19. A method according to claim 1, wherein the compound has the formula: ##STR00116## or a pharmaceutically acceptable salt thereof. 20. A method according to claim 1, wherein the compound has the formula: ##STR00117## or a pharmaceutically acceptable salt thereof. |
Details for Patent 9,540,410
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 02/12/2004 | ⤷ Try a Trial | 2032-11-13 |
Eli Lilly And Company | ERBITUX | cetuximab | Injection | 125084 | 03/28/2007 | ⤷ Try a Trial | 2032-11-13 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.